Vitamin D Receptor Polymorphisms and Efficacy of Vitamin D-Fortified Yogurt Drink in Patients With Type 2 Diabetes
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Study is a 12-week Double blind,controlled experiments designed to examine the possible effects of vitamin D receptor gene polymorphisms on the metabolic, inflammatory and oxidative stress markers in type 2 diabetic patients to vitamin D-fortified yogurt drink intake.
| Condition | Intervention |
|---|---|
|
Type 2 Diabetes Mellitus |
Dietary Supplement: Fortified Yogurt Drink Dietary Supplement: Plain Yogurt Drink |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Outcomes Assessor) |
| Official Title: | Determination of VDR Single Nucleotide Polymorphisms (SNPs ) and Their Rols in Efficacy of Vitamin D-fortified Yogurt Drink on the Metabolic-, Inflammatory - and Oxidative Stress Parameters in Type 2 Diabetic Patients |
- serum 25-hydroxyvitamin D [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
- Glycemic control [ Time Frame: 3 Months ] [ Designated as safety issue: Yes ]
- Inflammatory markers [ Time Frame: 3 Months ] [ Designated as safety issue: Yes ]
- Oxidative stress markers [ Time Frame: 3 Months ] [ Designated as safety issue: Yes ]
- Lipid profiles [ Time Frame: 3 Months ] [ Designated as safety issue: Yes ]
- Blood pressure [ Time Frame: 3 Months ] [ Designated as safety issue: Yes ]
| Enrollment: | 180 |
| Study Start Date: | October 2009 |
| Study Completion Date: | April 2011 |
| Primary Completion Date: | March 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Placebo Comparator: Plain Yogurt Drink
Daily intake of unfortified yogurt drink(500 ml) for 12 weeks
|
Dietary Supplement: Plain Yogurt Drink
Daily intake of unfortified yogurt drink(500 ml)for 12 weeks
Other Name: PYD
|
|
Experimental: VDR Genotype (aa)
Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
|
Dietary Supplement: Fortified Yogurt Drink
Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
Other Name: FYD
|
|
Experimental: VDR Genotype (AA)
Daily intake of yogurt drink fortified (500 ml) with 1000 IU vitamin D for 12 weeks
|
Dietary Supplement: Fortified Yogurt Drink
Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
Other Name: FYD
|
|
Experimental: VDR genotype (Aa)
Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
|
Dietary Supplement: Fortified Yogurt Drink
Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
Other Name: FYD
|
Detailed Description:
In a 12-week randomized controlled trial ( double-blind study), based on data on serum 25(OH)D changes from other studies (35), to achieve 1 standard deviation difference in circulating 25(OH)D with two-sided alpha of 0.05 and a beta of 0.2 after a 12-week intervention period, the sample size was calculated 40 individuals per treatment group. Considering 3 polymorphic variant groups and one control group which receives plain yogurt drink, 160 subjects are needed. Allowing for 10% attrition over 12 weeks of intervention, a total of 180 subjects are required. In treatment groups, all patients receive 500 ml per day of low-fat (1%) Yogurt Drink fortified with approximately 500IU of vitamin D3 . Control group receives 500 ml per day of plain (unfortified) Yogurt Drink. Metabolic, inflammatory and oxidative stress markers are evaluated at the beginning and in the end of the interventional period.
Eligibility| Ages Eligible for Study: | 30 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Type 2 diabetes
- Informed consent
- BMI between 25 to 35 kg/m2
- Age: 30-45 years old
- Willingness to maintain current body weight for the duration of the study
- Willingness to maintain baseline lifestyle activities and routines for the duration of the study
- Willingness to avoid the use of all over-the-counter or prescription vitamins, dietary supplements, and herbal products during the study
Exclusion Criteria:
- History of cardiovascular , Gastrointestinal , Renal disease and any other endocrinological disorders
- Subjects receiving vitamin D or omega-3 supplement
- Pregnancy , or lactation within the study period
- Treatment with insulin
- Treatment for weight reduction
- Treatment for reducing serum lipids
Contacts and Locations| Iran, Islamic Republic of | |
| Tehran, Iran, Islamic Republic of | |
| National Nutrition and Food Technology Research Institute | |
| Tehran, Iran, Islamic Republic of, 1981619573 | |
| National Nutrition and Food Technology Research Institute | |
| Tehran, Iran, Islamic Republic of, 19395-4741 | |
| Tirang Neyestani | |
| Tehran, Iran, Islamic Republic of | |
| Study Chair: | Tirang R. Neyestani, Ph.D. | National Nutrition & Food technology Research institute, P.O. Box 19395-4741 |
| Study Chair: | Abolghasem Djazayeri, Professor | Tehran University of Medical Sciences |
| Principal Investigator: | Sakineh Shab-Bidar, M.Sc. | Tehran University of Medical Sciences |
More Information
No publications provided by National Nutrition and Food Technology Institute
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Tirang R. Neyestani, associate professor, National Nutrition and Food Technology Institute |
| ClinicalTrials.gov Identifier: | NCT01236846 History of Changes |
| Other Study ID Numbers: | ABT-1236-RV |
| Study First Received: | August 9, 2010 |
| Last Updated: | April 25, 2012 |
| Health Authority: | Iran: Ministry of Health |
Keywords provided by National Nutrition and Food Technology Institute:
|
Vitamin D fortification Yogurt Drink Efficacy |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Vitamin D Ergocalciferols |
Vitamins Bone Density Conservation Agents Physiological Effects of Drugs Pharmacologic Actions Micronutrients Growth Substances |
ClinicalTrials.gov processed this record on May 23, 2013